SCHEMBL153752

SCHEMBL153752

Fc1c[nH]c2ncnc(Cl)c12

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.63
IRAK4 Q9NWZ3 1/20 0.44
TRPA1 O75762 4/20 0.43
LRRK2 Q5S007 5/20 0.42
BRAF P15056 1/20 0.39
TNNI3K Q59H18 1/20 0.39
NOTUM Q6P988 1/20 0.37
AURKA O14965 1/20 0.37
STK4 Q13043 1/20 0.36
STK3 Q13188 1/20 0.36
JAK3 P52333 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
AKT1 P31749 2/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
DYRK1A Q13627 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31329069 0.81 CHEK1 (0.66) CHEK1TRPA1LRRK2BRAFTNNI3K
SCHEMBL1598149 0.81 CHEK1 (0.66) CHEK1TRPA1LRRK2BRAFTNNI3K
SCHEMBL2323682 0.79 CHEK1 (0.63) CHEK1TRPA1LRRK2NOTUMAURKA
SCHEMBL30372928 0.78 LRRK2 (0.59) CHEK1LRRK2STK4STK3JAK3
SCHEMBL61206 0.78 CHEK1 (1.00) CHEK1TRPA1LRRK2NOTUMAURKA
SCHEMBL357993 0.78 CHEK1 (0.61) CHEK1IRAK4TRPA1BRAFTNNI3K
SCHEMBL154600 0.78 CHEK1 (0.61) CHEK1TRPA1BRAFTNNI3KNOTUM
SCHEMBL2321413 0.78 CHEK1 (0.61) CHEK1IRAK4TRPA1LRRK2NOTUM
SCHEMBL5019486 0.78 CHEK1 (0.61) CHEK1IRAK4TRPA1LRRK2NOTUM
SCHEMBL23544614 0.77 CHEK1 (0.56) CHEK1IRAK4TRPA1LRRK2NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005016878-A2 METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 2005-02-24 WO claimed
WO-2025235664-A1 PURINE NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2025-11-13 WO disclosed
US-12459950-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED (US) 2025-11-04 US disclosed
US-12440506-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED (US) 2025-10-14 US disclosed
EP-4552697-A2 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2025-05-14 EP disclosed
US-20250144125-A1 6-SUBSTITUTED- AND 6,7-DISUBSTITUTED-7-DEAZAPURINE RIBONUCLEOSIDE ANALOGUES UNIV LEUVEN KATH (BE) 2025-05-08 US disclosed
US-20250134869-A1 Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides PFIZER INC (US) 2025-05-01 US disclosed
EP-3514151-B1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2025-04-23 EP disclosed
US-20250041319-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS RIBOSCIENCE LLC 2025-02-06 US disclosed
US-12173026-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2024-12-24 US disclosed
WO-2007047793-A2 CYCLOPENTENOL NUCLEOSIDE COMPOUNDS, INTERMEDIATES FOR THEIR SYNTHESIS AND METHODS OF TREATING VIRAL INFECTIONS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2007-04-26 WO disclosed
EP-1761540-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2007-03-14 EP disclosed
WO-2006065335-A2 FLUORINATED PYRROLO[2,3-D]PYRIMIDINE NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION MERCK & CO., INC. (US) 2006-06-22 WO disclosed
WO-2005113556-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2005-12-01 WO disclosed
CN-1671727-A Antiviral 7-deaza-D-nucleosides and uses thereof MICROLOGIX BIOTECH INC (CA) 2005-09-21 CN disclosed
US-20050164960-A1 Methods of inhibiting orthopoxvirus replication with nucleoside compounds MERCK SHARP & DOHME CORP. 2005-07-28 US disclosed
EP-1527082-A2 ANTI-VIRAL 7-DEAZA D-NUCLEOSIDES AND USES THEREOF Micrologix Biotech, Inc. (CA) 2005-05-04 EP disclosed
WO-2005016878-A2 METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 2005-02-24 WO disclosed
US-20050026853-A1 Anti-viral 7-deaza D-nucleosides and uses thereof MICROLOGIX BIOTECH INC. (CA) 2005-02-03 US disclosed
WO-2004011478-A2 ANTI-VIRAL 7-DEAZA D-NUCLEOSIDES AND USES THEREOF MICROLOGIX BIOTECH INC. (CA) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459950-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRMT5, PRMT1, PRMT6 CHEK1 1069/4885IRAK4 3614/4885TRPA1 4883/4885
US-20050026853-A1 Anti-viral 7-deaza D-nucleosides and uses thereof ENTPD5, ADA, HAVCR2 CHEK1 4293/4885IRAK4 3346/4885TRPA1 4861/4885
US-20250041319-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS ENPP1, ENPP3, SMPD1 CHEK1 3644/4885IRAK4 4464/4885TRPA1 4787/4885
US-12173026-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 CHEK1 642/4885IRAK4 3709/4885TRPA1 4200/4885
US-20250134869-A1 Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides JAK2, JAK3, JAK1 CHEK1 339/4885IRAK4 108/4885TRPA1 1590/4885
US-12440506-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRMT5, PRMT1, PRMT6 CHEK1 456/4885IRAK4 3809/4885TRPA1 4879/4885
US-20250144125-A1 6-SUBSTITUTED- AND 6,7-DISUBSTITUTED-7-DEAZAPURINE RIBONUCLEOSIDE ANALOGUES NSUN2, MTAP, ADAR CHEK1 3389/4885IRAK4 1686/4885TRPA1 3706/4885
US-20050164960-A1 Methods of inhibiting orthopoxvirus replication with nucleoside compounds ITPA, PNP, NUDT1 CHEK1 2006/4885IRAK4 2243/4885TRPA1 4677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.